Segment Information

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segment Information

11. Segment Information

The CODM assesses performance for the life sciences segment based on net loss, which includes evaluating the progress of ongoing clinical trials. The life sciences segment is dedicated to developing off-the-shelf, allogeneic, NK cell-based therapies that are effective, safe and accessible for patients with devastating autoimmune diseases and cancers. The measure of segment assets is reported on the balance sheet as total assets. All long-lived assets are maintained in the United States. The following table contains information on segment profit or loss, including significant segment expenses (in thousands):

	THREE MONTHS ENDED MARCH 31,
	2025			2024
Revenue	$	—		$	251
Less:
AB-101		7,545			3,289
Other programs(a)		14			47
Personnel-related		9,573			6,815
Other(b)		5,039			4,592
Other income, net		1,860			529
Net loss	$	(20,311	)	$	(13,963	)

(a)Other programs primarily include costs associated with AB-201.

(b)Other primarily includes consultant, depreciation, rent, common area maintenance, lab supplies, legal, and insurance expenses.